Clinical Trials Browser

Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06238479 2026-05-22

EXCEED

Phase 1 Active not recruiting

490 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT04388852 2026-05-20

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Phase 1 Active not recruiting

65 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

NCT04846478 2026-05-12

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Phase 1 Active not recruiting

35 enrolled

Genitourinary

Prostatic Neoplasms

NCT04486755 2026-05-11

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

Phase 1 Active not recruiting

18 enrolled

Genitourinary

Prostatic Neoplasms

NCT02123758 2026-05-08

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Active not recruiting

57 enrolled

Genitourinary

Prostatic Neoplasms

NCT03523442 2026-05-08

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Active not recruiting

19 enrolled

Genitourinary

Prostatic Neoplasms

NCT04577833 2026-05-08

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Phase 1 Active not recruiting

136 enrolled

Genitourinary

Prostatic Neoplasms

NCT04644770 2026-05-08

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Phase 1 Active not recruiting

144 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04662580 2026-05-08

ARX517

Phase 1 Active not recruiting

183 enrolled

Genitourinary

Prostatic Neoplasms

NCT04898634 2026-05-08

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Phase 1 Active not recruiting

216 enrolled

Genitourinary

Prostatic Neoplasms

NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Phase 1 Active not recruiting

101 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06895811 2026-04-28

Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC

Phase 1 Active not recruiting

3 enrolled

Genitourinary

Prostatic Neoplasms

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Phase 1 Active not recruiting

200 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT06545942 2026-04-17

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

220 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07236112 2026-04-15

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

Phase 1 Active not recruiting

6 enrolled

Genitourinary

Prostatic Neoplasms

NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Phase 1 Active not recruiting

62 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

NCT06303713 2026-04-08

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Phase 1 Active not recruiting

37 enrolled

Genitourinary

Prostatic Neoplasms

NCT05079698 2026-04-07

A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer

Phase 1 Active not recruiting

29 enrolled

Genitourinary

Prostatic Neoplasms

NCT07214961 2026-04-07

ARTISAN

Phase 1 Active not recruiting

80 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04147806 2026-04-03

PROSINT

Phase 1 Active not recruiting

31 enrolled

Genitourinary

Prostatic Neoplasms

NCT04886986 2026-03-31

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

Phase 1 Active not recruiting

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Phase 1 Active not recruiting

499 enrolled

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT04514484 2026-03-23

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Phase 1 Active not recruiting

8 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05245006 2026-03-17

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Phase 1 Active not recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT07038369 2026-03-17

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Phase 1 Active not recruiting

134 enrolled

BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Phase 1 Active not recruiting

9 enrolled

Genitourinary

Prostatic Neoplasms

NCT02353819 2026-02-23

Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer

Phase 1 Active not recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT03089203 2026-02-23

CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

Phase 1 Active not recruiting

23 enrolled

Genitourinary

Prostatic Neoplasms

NCT06555796 2026-01-26

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Phase 1 Active not recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms

NCT01140373 2026-01-15

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

Phase 1 Active not recruiting

13 enrolled

Genitourinary

Prostatic Neoplasms

NCT05010200 2026-01-07

PGV-Prostate

Phase 1 Active not recruiting

27 enrolled

Genitourinary

Prostatic Neoplasms

NCT06229366 2025-12-22

ACCEL

Phase 1 Active not recruiting

142 enrolled

Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

120 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01923506 2025-11-26

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

Phase 1 Active not recruiting

26 enrolled

Genitourinary

Prostatic Neoplasms

NCT02023463 2025-11-25

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Phase 1 Active not recruiting

25 enrolled

Genitourinary

Prostatic Neoplasms

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Phase 1 Active not recruiting

15 enrolled 17 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT03269422 2025-09-30

Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)

Phase 1 Active not recruiting

35 enrolled

Genitourinary

Prostatic Neoplasms

NCT01655836 2025-09-11

High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

Phase 1 Active not recruiting

42 enrolled

Genitourinary

Prostatic Neoplasms

NCT06703437 2025-09-03

Long Acting Neuraxial Peri-prostatic Block in Cancer

Phase 1 Active not recruiting

12 enrolled

Genitourinary

Prostatic Neoplasms

NCT00977457 2025-08-19

Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery

Phase 1 Active not recruiting

1,045 enrolled

Genitourinary

Prostatic Neoplasms

NCT04457232 2025-07-15

FAPI PET Prost

Phase 1 Active not recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT03873805 2025-06-26

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Phase 1 Active not recruiting

14 enrolled 14 charts

Genitourinary

Prostatic Neoplasms

NCT05077098 2025-04-25

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

Phase 1 Active not recruiting

8 enrolled

Genitourinary

Prostatic Neoplasms

NCT04706962 2025-04-15

TH1902 in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

70 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05917860 2025-02-17

NeoADT-TULSA

Phase 1 Active not recruiting

15 enrolled

Genitourinary

Prostatic Neoplasms

NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

130 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06193993 2024-01-08

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

Phase 1 Active not recruiting

10 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Clinical Trials

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

EXCEED

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

ARX517

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer

ARTISAN

PROSINT

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer

CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

PGV-Prostate

ACCEL

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)

High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

Long Acting Neuraxial Peri-prostatic Block in Cancer

Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery

FAPI PET Prost

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

TH1902 in Patients With Advanced Solid Tumors

NeoADT-TULSA

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients